NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma-Reference-Cited by-同舟云学术

NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma

Published:2023-06 Issue: Volume:60 Page:102015
ISSN:2589-5370
Container-title:eClinicalMedicine
language:en
Short-container-title:eClinicalMedicine

Author:

McNamara Mairéad G.^ORCID,Swain Jayne,Craig Zoe,Sharma Rohini,Faluyi Olusola,Wadsley Jonathan,Morgan Carys,Wall Lucy R.,Chau Ian,Reed Nick,Sarker Debashis,Margetts Jane,Krell Daniel,Cave Judith,Sothi Sharmila,Anthoney Alan,Bell Christopher,Patel Alkesh,Oughton Jamie B.,Cairns David A.^ORCID,Mansoor Wasat,Lamarca Angela,Hubner Richard A.,Valle Juan W.

Publisher

Elsevier BV

Subject

General Medicine

Reference37 articles.

1. Trends in incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States;Dasari;JAMA Oncol,2017

2. Incidence and survival of neuroendocrine neoplasia in England 1995-2018: a retrospective, population-based study;White;Lancet Reg Health Eur,2022

3. Gastrointestinal neuroendocrine tumors in 2020;Ahmed;World J Gastrointest Oncol,2020

4. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal;Rindi;Mod Pathol,2018

5. The 2019 WHO classification of tumours of the digestive system;Nagtegaal;Histopathology,2020

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PRRT in high‐grade digestive neuroendocrine neoplasms (NET G3 and NEC);Journal of Neuroendocrinology;2024-09-07

2. Efficacy and Toxicity Analysis of mFOLFIRINOX in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms;Journal of the National Comprehensive Cancer Network;2024-07

3. Emerging Treatment Options for Neuroendocrine Neoplasms of Unknown Primary Origin: Current Evidence and Future Perspectives;Cancers;2024-05-27

4. A new schedule of one week on/one week off temozolomide as second-line treatment of advanced neuroendocrine carcinomas (TENEC-TRIAL): a multicenter, open-label, single-arm, phase II trial;ESMO Open;2024-05

5. Gastric neuroendocrine neoplasms;Nature Reviews Disease Primers;2024-04-11